Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019396 · ClinicalTrials.gov registry record · Phase 2
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
A Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00019396: Completed Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by National Cancer Institute (NCI).
NCT00019396 is a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019396, a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells. PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy in treating patients with metastatic melanoma or renal cell cancer.
Conditions Studied
Interventions
- DRUG Montanide ISA-51
- DRUG flt3 ligand
- DRUG gp100 antigen
- DRUG MART-1 antigen
- DRUG tyrosinase peptide
Study Locations (1)
Maryland
- Surgery Branch - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00019396 record still lists
NCT00019396 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 4 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Montanide ISA-51 is the first listed.
NCT00019396 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00019396 about?
NCT00019396 is a clinical study titled "flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer". RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells. PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy in t...
What is the current status of trial NCT00019396?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-02. Estimated completion is 2007-03.
What conditions does trial NCT00019396 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer.
What interventions are being tested in trial NCT00019396?
The interventions under investigation include: Montanide ISA-51 (DRUG), flt3 ligand (DRUG), gp100 antigen (DRUG), MART-1 antigen (DRUG), tyrosinase peptide (DRUG).
Who is sponsoring clinical trial NCT00019396?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00019396 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia